J&J keeps Alzheimer's focus with Alector collaboration
This article was originally published in Scrip
Executive Summary
Johnson & Johnson entered into a research collaboration with Alector, one of the companies in its biotechnology startup incubator in Northern California, to identify a therapeutic candidate against an undisclosed Alzheimer's disease target.